Research chemicalResearch chemicalPsychedelicTryptamine

4-HO-DPT

Also known as 4-hydroxy-N,N-dipropyltryptamine · 4-HO-DPT

Written by enwyReviewed 4 Aug 20262 sources0 comments

4-HO-DPT (4-hydroxy-N,N-dipropyltryptamine) is a synthetic psilocin-analogue psychedelic tryptamine described by Shulgin. It is used non-medically for its psychedelic effects. Human evidence is anecdotal and sparse; potency, kinetics and safety are essentially uncharacterised, with wide individual dose variation.

01 Overview

4-HO-DPT is a 4-hydroxytryptamine related to psilocin, bearing dipropyl groups on the nitrogen. It is among the more obscure research-chemical tryptamines, with limited user reports describing a psychedelic experience of moderate duration and variable visual intensity.

There are essentially no controlled human data and only sparse anecdotal reports, so dose ranges are highly approximate and vary between individuals. As with other serotonergic psychedelics, difficult psychological reactions and serotonergic side effects are possible, particularly at higher doses.

02 Mechanism

Serotonin 5-HT2A receptor agonist/partial agonist (classical psychedelic mechanism), as a 4-hydroxy tryptamine analogous to psilocin.

03 Dosing

Tier	Dose	Route	Notes
Threshold	5–10 mg	Oral	Highly approximate; very sparse data.
Common	15–30 mg	Oral	Onset ~20-45 min, duration ~4-6 h. Not clinically validated.
Strong	30–40 mg	Oral	Higher risk of overwhelming effects.

04 Effects

Effect	Magnitude	Evidence
Visual effectsVisual patterning and enhancement reported, variable in intensity.		Anecdotal
Mood alterationEuphoria or emotional variability reported at moderate doses.		Anecdotal
Altered cognitionShifts in thought and time perception typical of serotonergic psychedelics.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence
NauseaGastrointestinal discomfort during onset.	Mild	Common	Anecdotal
Cardiovascular stimulationIncreased heart rate and blood pressure.	Mild	Common	Anecdotal
Anxiety / challenging experienceAnxiety, confusion or panic, more likely at high doses or in poor setting.	Moderate	Common at higher doses	Anecdotal

06 Legal status

United Kingdom

Class A / tryptamine controls

Covered by UK tryptamine provisions. · as of Jan 2026

United States

Not federally scheduled by name; possible Federal Analogue Act exposure. · as of Jan 2026

07 References

TiHKAL: The ContinuationShulgin & Shulgin, 1997

New psychoactive substances monitoringEUDA (formerly EMCDDA)

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.